Equities research analysts at Cantor Fitzgerald began coverage on shares of Anteris Technologies Global (NASDAQ:AVR – Get Free Report) in a research report issued on Tuesday, MarketBeat.com reports. The brokerage set an “overweight” rating and a $9.00 price target on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 59.86% from the stock’s current price.
Separately, Barclays assumed coverage on Anteris Technologies Global in a research note on Tuesday. They issued an “overweight” rating and a $22.00 price objective on the stock.
Read Our Latest Research Report on Anteris Technologies Global
Anteris Technologies Global Price Performance
Anteris Technologies Global Company Profile
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
Further Reading
- Five stocks we like better than Anteris Technologies Global
- What is a Dividend King?
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- What is a Stock Market Index and How Do You Use Them?
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- 5 discounted opportunities for dividend growth investors
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.